Karuna Therapeutics (KRTX) Financial Analysis & Valuation | Quarter Chart
Karuna Therapeutics (KRTX)
KRTXPrice: $329.83
Fair Value: 🔒
🔒score
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for ... more
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transfor... more
Description
Shares
| Market Cap | $12.60B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | William Meury |
| IPO Date | 2019-06-28 | CAGR | — |
| Employees | 339 | Website | www.karunatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
KRTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $11.79B | P/E Ratio | -28.09 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 19264.95 | P/B Ratio | 9.72 |
| P/CF Ratio | -31.6 | P/FCF Ratio | -32.41 |
| EPS | $-11.74 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -93.85% | Gross Margin | -1.6% |
| Operating Margin | -756.54% | Profit Margin | -663.12% |
| ROE | -0.36% | ROA | -0.32% |
| ROCE | -0.39% | Current Ratio | 19.31 |
| Quick Ratio | 18.82 | Cash Ratio | 2.73 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | 91.14 | Piotroski Score | 1 |